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Abstract: Cyclodextrins (CDs) are a group of cyclic oligosaccharides produced from starch or starch
derivatives. They contain six (αCD), seven (βCD), eight (γCD), or more glucopyranose monomers
linked via α-1,4-glycosidic bonds. CDs have a truncated cone shape with a hydrophilic outer wall and
a less hydrophilic inner wall, the latter forming a more apolar internal cavity. Because of this special
architecture, CDs are soluble in water and can simultaneously host lipophilic guest molecules. The
major advantage of inclusion into CDs is increased aqueous solubility of such lipophilic substances.
Accordingly, we present studies where the complexation of natural compounds such as propolis and
dietary plant bioactives (e.g., tocotrienol, pentacyclic triterpenoids, curcumin) with γCD resulted
in improved stability, bioavailability, and bioactivity in various laboratory model organisms and in
humans. We also address safety aspects that may arise from increased bioavailability of plant extracts
or natural compounds owing to CD complexation. When orally administered, α- and βCD—which
are inert to intestinal digestion—are fermented by the human intestinal flora, while γCD is almost
completely degraded to glucose units by α-amylase. Hence, recent reports indicate that empty
γCD supplementation exhibits metabolic activity on its own, which may provide opportunities for
new applications.
Keywords: cyclodextrins; gamma-cyclodextrin; complex; ursolic acid; oleanolic acid; betulinic acid;
propolis; tocotrienol; curcumin
1. Introduction
Cyclodextrins (CDs), also known as cyclomaltoses, cycloamyloses, and Schardinger
dextrins, are a group of cyclic oligosaccharides that are produced from starch or starch
derivatives by the bacterial enzyme cyclodextrin glycosyltransferase (CGTase) [1,2]. CDs
contain six or more glucopyranose monomers linked via α-1,4-glycosidic bonds. The
most prominent members of the CD family are α- (six glucopyranose units), β- (seven
glucopyranose units), and γCD (eight glucopyranose units, Figure 1) [1]. Through the
specific steric arrangement of their glucose units, CDs are soluble in water and can function
as important complexation agents for a broad range of more lipophilic molecules, including
natural compounds and plant bioactives, with increasing use in industrial and research
applications [1,3]. The major advantage of the inclusion of lipophilic substances into
CDs is increased aqueous solubility with enhanced stability and bioavailability of these
guest molecules. In addition, CDs can be used to prevent drug-drug and drug-excipient
interactions, convert liquid drugs into microcrystalline powder, and reduce gastrointestinal
drug irritation [4].
This review aims to provide a short historical overview as well as a summary of the
synthesis, properties, pharmacokinetics, and safety of CDs. Furthermore, the differences
among the three main CD types are addressed with respect to their complex formation and
route of administration. The present state of knowledge regarding the stability, bioavail-
ability, and bioactivity of γCD complexes with selected natural compounds and dietary
plant bioactives is described. Finally, the biological activity of empty γCD is also reviewed.
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Figure 1. Chemical structures and physicochemical properties of the three main cyclodextrins α-, β-, and γ-cyclodextrin 
(from left to right αCD, βCD, and γCD). ID: Inner diameter; OD: Outer diameter. 1 From [2]. 2 From [5]. 3 From [1]. 
2. History of Cyclodextrins 
α- and βCD were discovered in 1891 by the French pharmacist and chemist Antoine 
Villiers as digestion products of potato starch obtained by using the bacterium Bacillus 
amylobacter (Figure 2). Villiers named the novel carbohydrates “cellulosines” α- and β-
dextrin and described them as crystalline and slightly sweet [6]. At the beginning of the 
20th century, the Austrian microbiologist Franz Schardinger, later known as the “found-
ing father” of CD chemistry, isolated CDs, which he termed “crystalline dextrins”, from 
several sources of starch following digestion by Bacillus macerans. Notably, B. macerans is 
still the most commonly used bacterial species for the production of CGTase to form CDs 
[2,6,7]. In the 1940s, the German chemist Freudenberg and his coworkers discovered γCD 
and subsequently solved the cyclic oligosaccharide structure of CD molecules. After dis-
covering the feasibility of preparing CD-inclusion complexes, Freudenberg, Cramer, and 
Plieninger obtained the first CD-related patent in 1953, which marks the starting point for 
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2. History of Cyclodextrins
α- nd βCD were discovered in 1891 by t e French pharmacis and ch mist Antoine
Villiers as digestion products of potato starch obt ined by using the bacterium Bacillus
amylobacter (Figure 2). Villiers named the novel carbohydrates “cellulosi es” α- and
β-dextrin and described them as crystalline and slightly sweet [6]. At the beginning
of the 20th century, the Austrian microbiologist Franz Schardinger, later known as the
“founding father” of CD chemistry, isolated CDs, which he termed “crystalline dextrins”,
from several sources of starch following digestion by Bacillus macerans. Notably, B. macerans
is still the most commonly used bacterial species for the production of CGTase to form
CDs [2,6,7]. In the 1940s, the German chemist Freudenberg and his coworkers discovered
γCD and subsequently solved the cyclic oligosaccharide structure of CD molecules. After
discovering the feasibility of preparing CD-inclusion complexes, Freudenberg, Cramer,
and Plieninger obtained the first CD-related patent in 1953, which marks the starting
point for the application of CDs in drug formulations [8], so that they were no longer just
part of academic research, but also part of industrial applications. In 1957, the American
chemist and biochemist Dexter French reported on two larger CDs, δ-dextrin and ε-dextrin,
with 9 and 10 glucose monomers, respectively [9,10]. However, compared to those of the
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smaller CDs, the physicochemical properties of these larger CDs were found to be less
suitable for complex formation [8]. In 1980, Saenger found that the amylase CGTase is
responsible for the conversion of starch or starch derivatives into CDs via a cyclization
reaction. Most importantly, this discovery enabled the mass production of CDs [2,7].
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reducing CDs from starch, amylose, and other polysaccharides. In addition, CGTase cat-
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hibits a weak hydrolyzing activity. A common feature of the reactions catalyzed by 
CGTase is the cleavage of an α-glycosidic bond. However, coupling is the reverse reaction 
of cyclization, where CD is the substrate and the generated linear malto-oligosaccharide 
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Roughly, the history of CDs can be classified into two main research fields. On the one
hand, a main focus is the complexation property of CDs and their role as host molecules to
improve the properties of guest molecules. As mentioned above, this traditional research
area started in the 1950s, has become well established and is still continuing. With the turn
of the new millennium, a new branch of CD research came to the fore, after the realization
that empty CDs exhibit bioactivity on their own and have potential health benefits. Hence,
CD molecules per se have received attention in research, and this topic is increasingly
recognized as important [6,11].
3. Synthesis of Cyclodextrins
The amylase CGTase (1,4-α-D-glucan 4-α-D-(1,4-α-D-glucano)-transferase) is a unique
extracellular enzyme capable of catalyzing the cyclization reaction to form nonreducing
CDs from starch, amylose, and other polysaccharides. In addition, CGTase catalyzes
two other main transglycosylation reactions (coupling, disproportionation) and exhibits a
weak hydrolyzing activity. A common feature of the reactions catalyzed by CGTase is the
cleavage of an α-glycosidic bond. However, coupling is the reverse reaction of cyclization,
where CD is the substrate and the generated linear malto-oligosaccharide is transferred
to an acceptor substrate. During disproportionation, a linear malto-oligosaccharide is
cleaved, and the shorter product is transferred to an acceptor substrate [1,12,13]. The
γ-cyclization reaction starts with the bond cleavage of polysaccharides. As a result, a
covalent intermediate is formed. The two ends of the linear chain of the intermediate
will be joined to form a cyclic oligosaccharide (Figure 3) [1,5]. The most crucial catalytic
amino acid residues implicated in bond cleavage are Asp229 and Glu257 [1]. During bond
formation, an α-1,4-glycosidic bond is closed again [1].
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CGTases are found in many bacteria, but have also been identified in archaea. Mainly
for historical reasons, CGTases from Bacillus species are the most extensively studied
enzymes [13]. All known CGTases convert starch to a mixture of α-, β-, and γCDs [12].
Depending on the enzyme source, the product mixtures differ in their relative amounts of
α-, β-, and γ-CDs. Hence, CGTases can be further classified according to their major CD
products [5]. To obtain individual α- and γCDs from the produced mixture, a costly and
time-consuming separation is needed [1]. Therefore, CGTases producing a high amount of
a single-type CD are often used and, in addition, have been genetically improved [1,13].
For example, Bacillus thuringiensis strain GU-2 was isolated from soil as a specific γCD-
producing strain with a purity of >95% when starch was used as the substrate. The
optimum conditions were reported to be pH 8.5 and 37 ◦C [15]. Compared to α- and γCD,
the separation and purification of βCD is relatively easy, and therefore rather inexpensive
due to its low solubility in water [13].
4. Properties of Cyclodextrins
The CDs of the so-called “first generation” or “parent cyclodextrins” are α-, β-, and
γCD. These polysaccharides consist of six, seven, or eight glucopyranose monomers linked
via α-1,4-glycosidic bonds (Figure 1) [2], forming a truncated cone shape with a central
axial cavity [16]. Main properties of the three CDs are listed in Figure 1.
The CD molecules have a hydrophilic outer wall because of the free hydroxyl groups
on the outside of the molecules and a less hydrophilic or hydrophobic inner wall im-
parted by the ether oxygen atoms in the glycosidic hemiacetals and the carbon-hydrogen
atoms [11]. Accordingly, CDs are soluble in water, yet can form complexes with many
hydrophobic guest molecules [2] through the slightly apolar internal cavities. Binding
studies by Heredia et al. [17] and Kajtár et al. [18] indicated that the internal polarity of
both β- and γCD are comparable with alcoholic solutions. Moreover, as shown by Street
and Acree [19], the estimated dielectric constants for the internal cavities of β- and γCD are
only slightly different. Since the depth of the cavities is similar in all parent CDs, their inner
diameter, which increases with the number of glucose subunits and determines the cavity
size (Figure 1), represents the main limiting factor for the ability to host organic molecules.
In good accordance to the increasing cavity size, αCD can harbor up to 6.6 molecules
water/molecule, βCD up to 11 molecules water/molecule, and γCD up to 17 molecules
water/molecule [16].
In addition to the central cavity, an essential feature of CDs is the location of the
hydroxyl groups [20]. There are secondary hydroxyl groups at the broadest end of the
toroid bonded to glucose units at C2 and C3 atoms (Figure 4a). At the opposite end, primary
hydroxyl groups are attached to glucose at C6 atoms. These hydroxymethyl groups define
the narrowest end of the CD molecule with the smallest cavity diameter. This is based on the
property of free rotation from hydroxymethyl groups [21]. Advantages from complexation
with CDs are higher water solubility, stability, diffusibility, and bioavailability of guest
molecules [22], and masking of ill smell and taste of guest molecules [3]. For example, a
propolis-γCD complex possesses a less pungent taste, is water soluble, and stable to heat
compared to propolis [23]. To further enhance the water solubility as well as the ability to
form inclusion complexes with parent CDs, changes in their free hydroxyl groups have
been made [24], resulting in CD derivatives such as 2-hydroxypropyl-γCD (HPγCD).
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parent CDs in that it is degraded by amylases to form glucose and other low molecular
weight sugar molecu s [5,22], which is important for oral administrat on and thereby calls
into question the ondigestible and no calori specifications. In turn, undigested γCD
is avail ble for fermentation. The m tabolic fate of α- and βCD is quite similar to that
i stible but fermentable carbohydrates [27], th reby providing nergy for
c lonic epithe ial cells, mainly in the form of bu yrate [28]. Furthermore, γCD shows the
highest water solubility [5,22]. In addition, γCD has a great advantage over αCD and βCD
in trapping larger molecules because it has the largest internal cavity volume (Figure 1) [1].
5. Absorption, Distribution, Metabolism, and Excretion of Cyclodextrins
Based on pharmacokinetic studies of CDs, orally administered CDs have low bioavail-
ability, and systemically absorbed CDs disappear rapidly from the body, mostly unmetabo-
lized in urine [29–32].
It has been shown that orally administered αCD at a dose of 200 mg/kg body weight
(BW) in rats exhibited an absorption rate of 1%. Excretion of intact αCD after oral gavage
was carried out via the kidneys. In this context, it is interesting that no intact αCD was
found in the feces, which indicates that αCD is completely fermented by the intestinal
microbiota, such as resistant starch or other types of fermentable dietary fiber [30]. Intra-
venous administration of 14C-labelled αCD to Wistar rats indicated half-lives of 21 and
26 min in blood in male and female rats, respectively. Furthermore, it has been shown
that αCD is excreted rapidly in urine, and only approximately 1.9% of systemic αCD is
eliminated with bile or saliva [30].
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Male Wistar rats employed by Kubota et al. (1996) received βCD orally at a dose of
500 mg/kg. Here, βCD reached the maximum plasma concentration within 40 min with an
absorption rate of 0.6% [29]. Intravenously administered βCD (25–100 mg/kg) exhibited
a half-life of 22–26 min in blood. The urinary excretion of intact βCD was approximately
90% within 10 h [29] or 24 h [32] after intravenous administration. According to these
findings, βCD is essentially eliminated via urine without undergoing relevant metabolism
in rats [29,32].
The enzyme β-amylase hydrolyses starch from the nonreducing end. Although
γCD is resistant to degradation by β-amylase, it is a substrate of salivary and pancreatic
α-amylase, whereas α- and βCD are not. The α-amylase hydrolyses α-bonds from large
polysaccharides such as starch. γCD is almost completely degraded to malto-triose, maltose,
and glucose, similar to the digestion of starch and linear dextrins [5,33,34]. The degradation
of γCD through α-amylase starts with a ring-opening reaction, which is the slowest step
of the degradation process of γCD. Linear malto-octaose is the result of this ring-opening
reaction, and can be further degraded by amylases [34]. It has been assumed that the
higher number of glucose molecules in γCD than in α- and βCD could be why γCD can be
degraded by α-amylase. The eight glucose monomers of γCD and the higher flexibility in
its circular structure result in higher susceptibility to the opening reaction of amylases [34].
Glucose is readily absorbed from the gastrointestinal tract, whereas the absorption of
intact γCD has been reported to be very low (0.02%) [31]. Moreover, the formation of
inclusion complexes with γCD decreased hydrolysis by α-amylase [35]. Intravenously
administered 14C-γCD indicated a half-life of 15–20 min in blood. Excretion kinetics
showed that approximately 90% of γCD was excreted in urine within 24 h [31].
6. Safety of Cyclodextrins
A high parenteral dose of βCD (200 mg/kg) in rats led to a decreased elimination
rate, suggesting that this high dose may be nephrotoxic [32]. The renal toxicity of high
parenteral doses of αCD [36] and βCD, respectively, has been reported elsewhere [36,37].
The occurrence of crystals in renal tissue might explain the nephrotoxicity [36,37]. However,
a dietary level of αCD up to 20% did not reveal adverse effects or signs of toxicity in studies
in rats and beagle dogs [38,39]. In healthy humans, treatment with 6 g αCD per day
for 12–14 weeks in a randomized, double-blind clinical trial was well tolerated. Only
mild gastrointestinal symptoms occurred and may be side effects related to oral αCD
administration [40]. The toxicity of βCD was studied in Sprague-Dawley rats and beagle
dogs receiving orally administered βCD for up to 52 weeks. The nontoxic effect level in rats
was 654 or 864 mg/kg/day for males or females, respectively, and 1831 or 1967 mg/kg/day
for male dogs or female dogs, respectively [41].
No signs of toxicity from γCD have been shown in acute toxicity studies in mice
and rats after oral, subcutaneous, intravenous, and intraperitoneal administration [5]. A
dietary level of up to 20% γCD has been shown to be well tolerated without toxic side
effects on the basis of studies in beagle dogs and Wister rats [5,42]. A dietary level of
up to 20% γCD in pregnant female rats did not reveal any fetotoxic, embryotoxic, or
teratogenic effects [43]. The oral toxicity of up to 20% γCD in the diet was examined in
beagle dogs over a 13-week period. The only treatment-related observed effects were
transient diarrhea and cecal enlargement. Both side effects are well-known physiological
responses to high doses of orally administered carbohydrates [42]. In humans, a single
oral dose of 50 g of carbohydrate from γCD or maltodextrin was administered in a double-
masked, randomized, crossover study with 32 healthy adult subjects. The treatments were
both well tolerated [44].
Overall, all three parent CDs are “generally recognized as safe” (GRAS) by the U.S.
FDA for use as a food additive [45–47]. Furthermore, βCD is approved in Europe as a
food additive (E459) with an acceptable daily intake (ADI) of 5 mg/kg BW per day [48].
However, the European Medicines Agency (EMA) recommends against the parenteral use
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of αCD and βCD due to their hepatotoxicity, although there has been one intravenous
product containing αCD on the market in Japan [49].
7. Cyclodextrin Inclusion Complexes
During complexation, guest molecules and CD molecules come into contact with each
other to unite and form a complex [50]. In most cases, one guest molecule forms a complex
with one CD molecule, resulting in a 1:1 type of CD complex (Figure 4b) [4,26,51].
In aqueous solutions, the internal cavity of CDs is occupied by water molecules. These
water molecules can be substituted by less polar guest molecules. The driving force is
the polar–apolar interaction between water and CD, which results in an energetically
unfavored environment. Complex formation takes place through substitution with an
appropriate guest molecule or, more commonly, some lipophilic moiety of the molecule,
which is less polar than water molecules [4,8]. This process reduces the total energy of the
system and causes a change in enthalpy, resulting in enhanced stability of the complex [21],
while no covalent bonds are formed or broken [4]. Therefore, water is almost necessary
in the formation of complexes [50]. During the complexation process, negative values of
free energy changes by the Gibbs equation have been shown for ursolic acid (UA) and
oleanolic acid (OA) with βCD and γCD, respectively, indicating that complexation was a
spontaneous process [24,26].
Various methods have been applied to prepare CD complexes: The solution method,
coprecipitation method, neutralization method, slurry method, kneading method, and
grinding method [4,50]. Factors such as temperature, amount of water, mixing time, and
drying conditions have to be adapted for each guest molecule and CD complex [50]. For
example, the triterpenoids UA, OA, betulinic acid (BA), and betulin (Bet) formed complexes
with CD when using the kneading method [52–54]. Both BA and Bet were encapsulated
in a γCD derivative with a molar ratio of 1:1. An equal quantity of ethanol and water
(1:1) was used as the solvent mixture. All materials were continuously kneaded together
for several minutes until the majority of the solvent mixture had been evaporated. The
resulting mixture was dried at room temperature for 24 h and then in an oven at 105 ◦C for
7 h. Then, the final product was pulverized and sieved [52,54].
The host-guest interaction of OA and UA with βCD was studied by Huang et al. [26].
They found that the kneading method resulted in products with higher drug loading,
but limited improvement in solubility. Therefore, the authors chose the stirring method
because the stirred products showed better inclusion and were more easily obtained [26].
Furthermore, it has been shown that both the stability constant (K) and the complexation
efficiency (CE) of UA were higher than those of OA. Because OA and UA have a very
similar chemical structure except for the location of one methyl group on ring E (Figure 5),
it has been assumed that ring E of both triterpenoids was encapsulated in the CD cavity [26].
For further information about the mechanism behind complexation, the hydrogen bonding
parameters were analyzed. Two intermolecular hydrogen bonds were revealed between
OA or UA and βCD. The hydrogen bonds were formed between the H atom on the carbonyl
group of UA (OA) and the O atom in βCD and between the O atom in the carbonyl group
of UA (OA) and the H atom bonding to the C atom in βCD [26,26]. The most stable
complex structure was reported to have the carboxyl group oriented to the center of the
CD cavity [24,26].
Another studied complex is caffeic acid phenethyl ester (CAPE)-γCD. The structure
of CAPE, a key anticancer phenolic compound in New Zealand propolis, as well as the
complex structure of CAPE-γCD, is shown Figure 4c [23]. It is suggested that the caffeic
acid moiety is encapsulated in the CD cavity.
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8. Application of Cyclodextrins
In 2017, approximately 70% f global CD production consisted of βCD, while the
shares of αCD and γCD were approximately 15% a d 5%, re ectively. However, due to
its favorable toxicological rofile, γCD, which was initially less produced, is becoming
increasingly attractive as a pharmaceutical excipient [5]. In Japan, native CDs are regarded
as natural products, resulting in usage without many restrictions both in medicines and
in foods [11]. CDs have been used in food and pharmaceutical products for many years,
largely to form inclusion complexes with problematic drugs to enhance their solubility [55].
In addition, previous studies have shown that CDs are useful as an antibacterial food
packaging material when forming inclusion complexes with natural antimicrobial agents
such as thymol and carvacrol [56–65]. This embedment of an antibacterial agent into
food packaging m teri l is one strategy to inhibit bacterial growth. Mostly, βCD was
successfully em loyed as a host m lecule. However, Aytac et al. [56] tested thymol-γCD
inclusion co plex-encapsulated electrospun zein n nofibrous webs (zein-THY-γCD-NF)
as a potential food packa ing material for meat sam les. The electrospun nanofibers were
prepared from a solution of THY-γCD complex-incorporated zein. The antibacterial activity
of zein-THY-γCD-NF against Escherichia coli and Staphylococcus aureus was higher than
that of zein-THY-NF without γCD. Therefore, the webs are of interest for application as
antibacterial food packaging materials [56].
As reported by Fenyvesi, Vikmon, and Szente [27], the food application of CDs started
in the 1970s. In particular, γCD has received much attention in oral bioavailability exper-
iments and is regarded as a promising nutrition delivery system [22]. An overview of
bioavailability and bioactivity of inclusion complexes of tocotrienols, pentacyclic triter-
penoids, propolis and curcumin with γCD is given in Table 1. γCD can stabilize diverse
food factors, such as flavors, sensitive colors, fat-soluble vitamins, polyunsaturated fatty
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acids, and emulsions of fats and oils. Such inclusion complexes are useful for the formu-
lation of meal replacements in powder form and of dietary supplements [33]. However,
one must keep in mind that hydrophilic CDs can act only as carrier materials for lipophilic
guest molecules in oral administration by helping to transport them safely through an
aqueous medium to the absorption surface of the gastrointestinal tract [66], thereby in-
creasing their stability only until they permeate biological membranes of, for example, the
intestinal epithelium.
Since CDs are poorly absorbed through biological membranes due to their relatively
high molecular weight and large number of hydrogen donors and acceptors [4], it is not
surprising that they usually do not increase the permeability of hydrophilic guest molecules
through lipophilic biological membranes [4]. However, CDs can stabilize lipophilic guest
molecules until they reach the unstirred water layer adjacent to the membrane surface of the
biological barrier [4]. Generally, only a free form of the lipophilic guest molecule is able to
penetrate the lipophilic biological membrane. Binding within the CD cavity is a reversible
process, and the free and complexed forms of the drug are in equilibrium in solution [66].
This equilibrium is compound-specific. Accordingly, CDs cannot increase the bioavailability
of every kind of molecule. For example, Class II drugs (Biopharmaceutics Classification
System categories) have poor aqueous solubility, but show good membrane permeability.
Here, complexation with CDs can enhance oral bioavailability by increasing diffusion
to the mucosal surface. It has been reported that in this case, the most important factor
inhibiting bioavailability is the low aqueous solubility of the drugs, which hinders their
dissociation from the molecule as well as their permeation through the water layer adjacent
to the membrane surface [4]. The bioavailability of Class I drugs cannot be improved by
CDs. They are defined as highly water soluble and highly membrane permeable, and
therefore have good bioavailability after oral administration [4]. Hence, such compounds
are generally not encapsulated into CDs to enhance their bioavailability. A detailed review
of drug absorption after oral administration and other application routes is given by
Loftsson et al. [4] and Uekama et al. [66].
Regarding the use of CDs in pharmaceutical products to form complexes with lipophilic
drugs, parenteral application also matters. It should be noted that parenteral adminis-
tration is mainly suitable for βCD derivatives such as HPβCD. αCD and βCD are not
recommended because of their reported nephrotoxicity. The low aqueous solubility of βCD
is also not an advantage for its use as a parenteral drug [49]. Similarly, γCD, which forms
visible aggregates in aqueous solutions, is not suitable for parenteral formulations [21].
Furthermore, CDs have a short half-life in systemic circulation and a high excretion rate in
urine, as described above. In the short time in systemic circulation, the complex may not
reach its target organ. Otherwise, the complex may dissociate before it reaches the drug
target organ or tissue [66].
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Table 1. Bioavailability and bioactivity of inclusion complexes of tocotrienols, pentacyclic triterpenoids, propolis, and curcumin with γ-cyclodextrin.




n = 5–8 Oral 13.9 mg T3




increased plasma and tissue
concentration of T3
Ikeda et al. 2014 [67]
T3-rich fraction (TRF) from rice
bran and γCD
C57BL/6 mice
n = 3 (bioavailability)
n = 12–15
(bioactivity)
Oral 2.79 mg TRF




Miyoshi et al. 2011 [22]
T3 and γCD
Caenorhabditis elegans




Oral 26, 86, and 259 µg T3 Prolonged lifespan Kashima et al. 2012 [68]
T3 and γCD C57BL/6 micen = 6–8 Oral 100 mg T3/kg diet
Increased mitochondrial
membrane potential and ATP
levels in aging brain
Schloesser et al. 2015 [69]




n = 6 Dermal
200 µL 2% aqueous
solution
No modification in TWL;
increased skin-pH;
small change of erythema;
small difference in stratum
corneum moisture content;
anti-tumor activity
Soica et al. 2014 [53]
Betulin (Bet) and octakis-γCD 1:1 C57BL/6 micen = 5
Subcutaneous
injection 20 mg Bet/BW
Decreased tumor volume;
decreased tumor weight Soica et al. 2012 [54]





injection 100 mg BA/kg
Decreased tumor volume;
decreased tumor weight;
decreased melanin, erythema, and
TWL levels
Soica et al. 2014 [52]
UA and γCD Wistar ratsn = 6 Intragastric 20 mg UA
Increased liver regeneration;
increased hepatocyte growth
factor liver expression and plasma
levels
Žaloudková et al. 2020 [70]
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Table 1. Cont.
Substances and Cyclodextrins Molar Ratio Model Organism Administration Dose Outcome Authors




elevated hepatic fat accumulation;
increased hepatic PPARγ, CD36,
CYP7A1, CYP3A, and GSTA1
levels;
increased plasma cholesterol level
Wüpper et al. 2020 [71]
Brazilian green propolis
supercritical extract (GPSE) and
γCD
C57BL/6 mice




Decreased hepatic TNFα and Sap
mRNA level;
anti-inflammatory properties
Rimbach et al. 2017 [72]
Caffeic acid phenethyl ester






anti-metastatic properties Wadhwa et al. 2016 [73]
CAPE and γCD A549 and HT1080cells
Higher cytotoxicity;
higher solubility in a mimicked
intestinal environment
Ishida et al. 2018 [23]
GPSE and γCD 1:1 BALB/c nude micen = 3 Oral
GPSE-γCD (containing










decreased number of adenomas Cho et al. 2016 [75]





Improved solubility and stability
in the GIT;
enhanced intestinal absorption of
T3
increased plasma and tissue
concentration of T3
Purpura et al. 2018 [76]
AUC, area under the curve; BA, betulinic acid; Bet, betulin; CAPE, caffeic acid phenethyl ester; CD36, CD36 molecule; CYP3A, cytochrome P450, family 3, subfamily a; CYP7A1, cytochrome P450, family 7, subfamily a,
polypeptide 1; GIT, gastrointestinal tract; GPSE, green propolis supercritical extract; GSTA1, glutathione S-transferase, alpha 1; HPγCD; 2-hydroxypropyl-γCD; KTE, Kuding tea extract; OA, oleanolic acid; PPARγ,
hepatic peroxisome proliferator activated receptor gamma; Sap, serum amyloid P; T3, tocotrienol; TNFα, tumour necrosis factor alpha; TRF, T3-rich fraction; TWL, transepidermal water loss; UA, ursolic acid; γCD,
gamma-cyclodextrin.
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8.1. Inclusion of Tocotrienol in γ-Cyclodextrin Increased Its Bioavailability and Bioactivity
A study in male Wistar rats examined the effects of different tocotrienol emulsions
(13.9 mg tocotrienol) with or without γCD on γ-tocotrienol (for chemical structure, see
Figure 5) concentrations in plasma and tissues. At 3 h after the oral administration of
tocotrienol, tocotrienol with γCD, or tocotrienol/γCD-complex, the complex of tocotrienol
with γCD led to elevated plasma and tissue concentrations of γ-tocotrienol compared
to the simultaneous administration of tocotrienol and γCD. The authors suggested that
complexation causes improved solubility and stability of tocotrienol in the gastrointestinal
tract, thereby enhancing its intestinal absorption. Pretreatment with the detergent Triton
and subsequent oral gavage of the different emulsions verified this suggestion in the
laboratory rodents. The rats that were given the Triton complex exhibited higher plasma γ-
tocotrienol concentrations than the animals in the other two groups. The study also clarified
that the tissue accumulation of tocotrienol is less regulated than plasma concentration [67].
It has also been demonstrated that the inclusion of γ-tocotrienol in γCD significantly
improved the oral bioavailability and physiological activity of γ-tocotrienol in young
C57BL/6 mice. The mice of the control group received 2.79 mg of a γ-tocotrienol-rich
fraction extracted from rice bran, while the complex group obtained an equivalent dose of
the γ-tocotrienol-rich fraction included in γCD. Complexation led to a 1.4-fold increase
in the area under the curve of γ-tocotrienol plasma concentration compared to the γ-
tocotrienol-rich fraction only [22]. In addition, the complexation of tocotrienols with
γCD resulted in a prolonged life span in the nematode Caenorhabditis elegans compared
to worms receiving pure γCD or pure tocotrienols. Initially, it was observed that the
nematodes absorbed a fluorescent dye, which was encapsulated in γCD for this assay,
from the gastrointestinal tract and accumulated the dye in the cytoplasm of the intestinal
cells. After testing the ingestion of γCD inclusion compounds, the oral administration of
tocotrienols in γCDs was analyzed. Accordingly, the authors suggested that γCD is an
excellent vehicle for the oral gavage of hydrophobic substances such as tocotrienol [68].
Schloesser et al. [69] evaluated the effect of a dietary tocotrienol-γCD complex on an
ageing brain phenotype in mice. Male middle-aged C57BL/6J mice received a high-fat,
high-sugar Western-type diet with or without (control) tocotrienol-γCD complex for up to
24 weeks. The tocotrienol content was 100 mg/kg diet. Examination of the brain revealed
significantly increased mitochondrial membrane potential and ATP levels in the complex
mice compared to the controls [69]. Unfortunately, the authors did not include a control
group with tocotrienols only.
In summary, tocotrienol exhibits improved bioavailability through enhanced solubility
and stability in the gastrointestinal tract, and therefore enhanced bioactivity in various
laboratory model organisms, attributable to encapsulation into CDs.
8.2. Pentacyclic Triterpenoids Encapsulated in γ-Cyclodextrin
Pentacyclic triterpenoids such as UA have been reported to act as chemopreven-
tive agents [77,78]. However, due to their low solubility and limited oral bioavailabil-
ity [79], new approaches, such as encapsulation into CDs, have been introduced to enhance
bioavailability and bioactivity. Several cell culture studies have demonstrated that complex
formulations of triterpenoids and CDs could improve the anticancer activity of triter-
penoids [24,51,53,80]. This seems somewhat questionable, especially when looking at
studies where a significant effect was shown in vivo, but not in vitro [52,54]. However,
a possible explanation for the improved in vitro anticancer activity might be that CDs
enhance the cellular uptake of drugs [24] by simply increasing their solubility in aque-
ous media.
Soica et al. [53] found synergistic antiproliferative activity of a mixture of OA and
UA (for chemical structure, see Figure 5) encapsulated in 2-hydroxypropyl-γ-cyclodextrin
(HPγCD) when applied in a chemically (7,12-dimethylbenz(a)-anthracene/12-O-tetradecan
oyl-phorbol-13-acetate) induced and UV-induced murine skin cancer model. SKH1 female
mice were treated 30 min before the application of carcinogens with either 200 µL of a 2%
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aqueous solution of OA-HPγCD, UA-HPγCD, or OA/UA-HPγCD. The delta of transepi-
dermal water loss (TWL) was in the control group at approximately 25 units/six weeks.
The mice treated with UA-HPγCD and OA/UA-HPγCD showed practically no modifi-
cation in TWL. The application of OA/UA-HPγCD led to the greatest increase in skin
pH. The evaluation of erythema, an important skin parameter involved in the assessment
of drug or chemical irritative potential, indicated a change of more than 230 units after
six weeks for the control group. However, only a small difference was documented for
the mice who received UA-HPγCD or OA/UA-HPγCD. Similar results were reported for
water loss from the stratum corneum [53].
Betulin (Bet) and betulinic acid (BA) (Figure 5) were encapsulated in octakis-[6-deoxy-
6-(2-sulfanyl ethanesulfonate)]-γCD (OγCD), a γCD derivative, to analyze their antitumor
activity in a B164A5/C57BL/6J mouse melanoma model [52,54]. At 2 days after the
inoculation of B164A5 cells in mice, the Bet-OγCD complex was given intraperitoneally
daily for 14 days at a concentration of 20 mg Bet/BW [54]. In BA-OγCD-treated mice,
the complex was administered intraperitoneally 1 day after cell inoculation at a dose of
100 mg/kg daily for 3 weeks [52]. Both treatments significantly inhibited tumor growth in
mice compared to that in untreated laboratory animals [52,54]. BA-OγCD administration
further led to decreased melanin, erythema, and TWL levels compared to control mice [52].
Natural sources of UA (homogenate apple peel, HAP, and micronized apple peel, MAP)
were compared with encapsulated UA in βCD and γCD, respectively, regarding their
impact on liver regeneration. Therefore, male Wistar rats received 20 mg UA daily for
7 days via intragastric gavage. On day 6, a partial hepatectomy (70%) was conducted.
UA-treated rats showed increased liver regeneration in comparison to untreated mice. In
particular, the UA complex with γCD exhibited good results. Plasma levels and expression
of hepatocyte growth factor in the liver were significantly increased in the high-fat diet-
UA-γCD group compared to the control group [70].
However, in a study that used dietary Kuding tea extract as a UA source (KTE, 7.12%)
encapsulated in 12.88% γCD (comprising 150 mg UA/kg BW), young male C57BL/6 mice
had increased liver weight and hepatic fat accumulation compared to control mice, which
received only a high-fat, high-fructose, Western-type diet for 6 weeks. In addition, the
mice from the complex group showed increased hepatic peroxisome proliferator activated
receptor gamma (Pparγ) and CD36 molecule (Cd36) mRNA levels as well as elevated
plasma cholesterol levels and increased cytochrome P450, family 7, subfamily a, polypep-
tide 1 (CYP7A1) mRNA, and protein levels. Analyzing the enzymes of hepatic xenobiotic
metabolism showed that there was a substantial elevation of cytochrome P450, family 3,
subfamily a (CYP3A) and glutathione S-transferase, alpha 1 (GSTA1) mRNA, and protein
levels in KTE-γCD mice. Pure UA-treated mice exhibited a moderate elevation of CYP3A
and GSTA1. In line with the assumption that CDs can mask the taste of guest molecules [3],
the study demonstrated that mice receiving a diet with bitter-tasting KTE alone completely
refused this diet, while the diet supplemented with KTE-γCD was eaten by mice [71]. This
study may show the other side of the coin of some inclusion complex formulations. By
encapsulating bioactive compounds, one may not only increase their positive biological
effects, but also promote some adverse effects, such as hepatotoxicity.
8.3. Propolis, Propolis Extract, or Phytochemicals Isolated from Propolis Encapsulated
in γ-Cyclodextrin
Brazilian green propolis supercritical extract (GPSE) has been reported to be rich in
artepillin C (3,5-diprenyl-4 hydroxycinnamic acid, Figure 5) and to stimulate immune
function. Accordingly, dietary GPSE encapsulated in γCD (2.3 g/kg GPSE-γCD) showed
anti-inflammatory properties in female C57BL/6 mice after 10 weeks of supplementation.
Hepatic gene expression of tumor necrosis factor alpha (TNFα) and serum amyloid P (Sap)
was significantly decreased in GPSE-γCD-fed mice compared to the control group and
the γCD-vehicle group, respectively [72]. Moreover, there are several reports on propolis
in combination with γCD and its anticancer and antimetastatic activities [73–75]. Caffeic
acid phenethyl ester (CAPE, Figure 4), a key phenolic component in New Zealand propo-
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lis, showed antitumor and antimetastatic potency in female Balb/c nude mice, and the
complexation of CAPE with γCD enhanced its activities. γCD per se did not exhibit any
bioactivity. The human fibrosarcoma cell line HT1080 was injected subcutaneously into
the abdomen of mice and into the tail vein. Starting one day after injection, treatment
with CAPE or CAPE-γCD was performed on every alternate day. Mice received either
intraperitoneal or oral administration of CAPE for up to 30 days. For both routes of admin-
istration, CAPE showed significant tumor suppression and reduction in lung metastasis.
CAPE-γCD-treated mice exhibited increased antitumor and antimetastatic activities com-
pared to pure CAPE [73]. According to the findings by Wadhwa et al. [73], in an in vitro
cell viability assay, CAPE-γCD revealed higher cytotoxicity in A549 and HT1080 cells than
CAPE alone [23]. In addition, the comparison of CAPE and CAPE-γCD solubility in 1.0%
taurocholic acid solution showed that complexation with γCD increased the solubility
of CAPE in a mimicked intestinal environment [23], possibly resulting in higher tumor
suppression activity, as reported in an earlier study [73]. In this context, it is interesting that
CAPE alone is vulnerable to digestive enzymes such as secreted esterases. However, when
encapsulated in γCD, CAPE is protected and shows enhanced activity [73]. The antitumor
properties of GPSE from Brazilian green propolis were also examined. GPSE, containing
9.6% artepillin C and GPSE-γCD, containing 3% artepillin C, was orally administered to
BALB/c nude mice beginning 1 day after subcutaneous tumor xenografts for 3 weeks. The
authors observed decreased tumor growth in mice fed GPSE and GPSE-γCD compared to
untreated mice. The data on GPSE alone and with γCD regarding tumor growth suggested
that complexation results in a more effective molecule [74].
Cho et al. [75] reported on C57BL/6J-ApcMin/+/J mice that received either a control
diet for a lean model or a high-fat diet for an obese model supplemented with γCD
and propolis (containing γCD), for 8 weeks. The chosen mouse model tends to develop
intestinal cancer with adenomas. In the lean model, γCD and propolis-treated mice showed
decreased neoplastic progression. Supplementation with propolis led to a further decrease
in the number of adenomas compared to the control diet [75]. However, since γCD also
affects intestinal tumor development, it is not exactly clear what part propolis plays in
this effect.
8.4. Increased Bioavailability of Curcumin by Complexation with γ-Cyclodextrin in Humans
Curcumin (Figure 5) is the main bioactive hydrophobic polyphenolic compound from
the so-called curcuminoids provided by turmeric, a member of the ginger family [76,81].
Previous studies have shown that curcumin possesses various pharmacological activities,
such as antioxidant, anti-inflammatory, and neuroprotective properties [82]. However, the
metabolism of curcumin, particularly in the intestine and liver, determines its bioavailabil-
ity and bioactivity [81]. Due to the low water solubility and poor intestinal absorption of
curcumin, different formulations have been developed to enhance its bioavailability [76].
In this context, Purpura et al. [76] analyzed the pharmacokinetics of a standardized un-
formulated curcumin extract (StdC), a γCD-curcumin formulation (C-γCD), a curcumin
phytosome formulation, and a curcumin formulation with essential oils of turmeric ex-
tracted from the rhizome in a double-blind, crossover study in 12 healthy human subjects.
The curcumin content in C-γCD was determined to be 348 mg. In addition, the complex
formulation contained demethoxycurcumin and bisdemethoxycurcumin, resulting in a
total curcuminoid content of 371 mg. Complexation with γCD significantly increased
the bioavailability of curcumin (85-fold) and total curcuminoids (39-fold) compared to
StdC. Plasma levels of curcuminoids were measured by HPLC-MS/MS analysis up to 12 h
after the intake of hard gel capsules of each of the different curcumin formulations. The
peak concentration of curcumin from C-γCD in plasma was 73 ng/mL, achieved after 1 h.
However, the peak curcumin concentration after StdC intake was 0.5 ng/mL after 12 h [76].
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8.5. Metabolic Activity of Empty γ-Cyclodextrin
As mentioned above, the propolis-γCD study by Cho et al. [75] also revealed an
unexpected beneficial effect of γCD supplementation per se. C57BL/6J-ApcMin/+/J
mice were fed either a control diet for a lean model or a high-fat diet for an obese model
supplemented with γCD and propolis (containing γCD) for 8 weeks. Both control groups
treated with γCD showed modulation of intestinal tumor development. In the obese state,
dietary γCD led to the lowest number and size of adenomas and concurrent to the highest
percentage of lesions with low grades of dysplasia in mice. Interestingly, the laboratory
animals supplemented with propolis (containing γCD) did not show this reduction in
neoplastic burden, indicating that propolis counteracted these effects. It has been assumed
that the effect of dietary γCD resulted from enhanced levels of apoptosis in intestinal tissue,
achieved by butyrate derived from γCD metabolism [75].
Another interesting biological effect of empty γCD was provided by Asp et al. [44].
Thirty-two healthy adult subjects received 50 g of carbohydrate from either γCD or mal-
todextrin during a double-blind, randomized crossover study. Plasma glucose and serum
insulin levels were reported for up to 180 min postprandial. Intake of γCD led to a moder-
ate and gradual increase in both glycaemia parameters. The area under the curve (AUC)
of plasma glucose was 45% reduced compared to maltodextrin. Consequently, the AUC
of serum insulin was reduced by 49% by γCD compared to maltodextrin. Monitored
breath hydrogen excretion showed no differences between the two carbohydrate sources,
indicating that γCD is fully hydrolyzed in the small intestine. In comparison with rapidly
digested maltodextrin, γCD is assumed to be a slowly digested carbohydrate, resulting in
reduced postprandial glycaemia [44]. In line with this assumption, it has been reported that
dietary γCD leads to increased endurance in C57BL/6 mice, probably due to a prolonged
supply of glucose during exercise. The laboratory animals received a control diet or a diet
supplemented with 12.88% γCD for 6 weeks. Voluntary activity was monitored via the
wheel running behavior of mice. The γCD-treated animals covered a significantly larger
distance per night and were active significantly longer during the night than the control
mice. Furthermore, adding γCD to the diet led to a significantly better performance of
mice in the inverted screen test, suggesting that these animals showed enhanced muscle
strength. It was also observed that dietary γCD had some slight antiglycemic effects [83].
The existing literature data demonstrate that the γCD derivative HPγCD may act
as a therapeutic approach for Niemann-Pick type C disease (NPC) [84–88], which is a
fatal neurodegenerative disorder characterized by a massive accumulation of free choles-
terol and other lipids in late endosomes and lysosomes. In addition, NPC1-deficient cells
showed defects in autophagy [89,90]. In line with this assumption, it has been reported
that HPγCD alleviates cholesterol accumulation in NPC1 patient-derived fibroblasts by
modulating lysosomal dynamics and functions as well as enhancing autophagic activ-
ity [84,85,87,91]. The cholesterol-binding capacity of HPγCD is still lower than that of
HPβCD [86,91], but the same applies for its ototoxicity [86]. Therefore, HPγCD might be
a more promising drug candidate than HPβCD for the treatment of NPC. In particular,
HPγCD alleviates lysosomal cholesterol accumulation in NPC1-deficient cells to the same
degree as HPβCD [84], or even more effectively [87]. Moreover, liver dysfunction and
cholesterol accumulation were enhanced by the subcutaneous injection of HPγCD in NPC
model mice [87]. Recent molecular research has indicated that the effects of HPγCD are
partly mediated by transcription factor EB, which is a regulator of lysosomal functions
and autophagy [84]. However, the underlying mechanism of action remains to be clarified.
Hoque et al. [88] showed that both HPβCD and HPγCD (but not HPαCD) reduced choles-
terol and sphingolipid accumulation solely in Npc1-null Chinese hamster ovary cells, but
not in the corresponding control wild-type cells.
9. Conclusions and Outlook
Increasing the stability, bioavailability, and bioactivity of natural compounds and
plant bioactives is an important issue in food science and pharmaceutics. As reviewed
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here, this goal can be achieved by encapsulating these often lipophilic molecules in γCD.
A growing number of studies indicate that such CD complexes often lead to enhanced
biological/pharmacological efficiency, increased stability, and better taste and odor.
However, one should consider that improving the bioavailability of dietary plant
bioactives may be accompanied by some risks, and a critical evaluation as well as a risk
assessment is needed. Encapsulation enables the intake of higher dosages of natural
compounds and plant bioactives. As shown for KTE encapsulated in γCD, high dietary
supplementation can lead to an increased hepatic phase I and phase II response [71]. Hence,
improving the bioavailability of plant bioactives that undergo biotransformation can cause
hepatotoxicity due to exceeding the toxicity threshold or can lead to herb-drug interactions,
thereby affecting medical treatment [92]. In this regard, it is notable that the number of
liver injury cases in the United States associated with dietary supplementation of herbal
sources is actually increasing [93].
Similarly, the complexation of natural products such as the bee product propolis could
also increase the bioavailability of potential allergens. Propolis allergies per se were more
of an occupational disease affecting beekeepers in the past. However, since propolis is
frequently included in dietary supplements, more and more, an increasing number of
people are affected by this allergy [94].
Moreover, by complexing herbal extracts into CDs, one may increase the bioavailability
of undesirable substances such as pesticides or contaminants. The selection and quality of
the raw material is therefore of particular importance. It should also be considered that
CDs mask the bitter taste and odor of their complexation agents, as reported for KTE. A
bitter taste often results in food aversion by animals, thereby protecting them against the
consumption of toxic compounds, although not all bitter compounds are toxic [95].
CDs have a long history as host molecules in inclusion complexes and were long
presumed to be inert molecules. However, only recently has it become evident that CDs
are not just carrier molecules, but also undergo digestion and fermentation in the digestive
tract. In particular, the first studies on γCD supplementation revealed promising effects on
energy metabolism. Therefore, the impact of empty CDs on metabolism and their possible
nutritional or pharmaceutical applications need additional investigation.
Author Contributions: Conceptualization, S.W., K.L., and G.R.; methodology, S.W.; investigation,
S.W.; writing—original draft preparation, S.W.; writing—review and editing, S.W., K.L., and G.R.;
visualization, S.W.; supervision, G.R.; project administration, G.R.; funding acquisition, S.W. All
authors have read and agreed to the published version of the manuscript.
Funding: The authors acknowledge the financial support by Land Schleswig-Holstein within the
funding program “Open Access Publikationsfonds”.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Data sharing not applicable.
Conflicts of Interest: G.R. has received funding from CycloChem Bio Co., Ltd., a company selling
cyclodextrins in previous studies.
References
1. Li, Z.; Wang, M.; Wang, F.; Gu, Z.; Du, G.; Wu, J.; Chen, J. γ-Cyclodextrin: A review on enzymatic production and applications.
Appl. Microbiol. Biotechnol. 2007, 77, 245–255. [CrossRef]
2. Del Valle, E. Cyclodextrins and their uses: A review. Process. Biochem. 2004, 39, 1033–1046. [CrossRef]
3. Singh, M.; Sharma, R.; Banerjee, U. Biotechnological applications of cyclodextrins. Biotechnol. Adv. 2002, 20, 341–359. [CrossRef]
4. Loftsson, T.; Jarho, P.; Másson, M.; Järvinen, T. Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2005, 2, 335–351.
[CrossRef]
5. Saokham, P.; Loftsson, T. γ-Cyclodextrin. Int. J. Pharm. 2017, 516, 278–292. [CrossRef]
6. Crini, G. Review: A history of cyclodextrins. Chem. Rev. 2014, 114, 10940–10975. [CrossRef] [PubMed]
7. Booij, L.H.D.J. Cyclodextrins and the emergence of sugammadex. Anaesthesia 2009, 64, 31–37. [CrossRef]
8. Szejtli, J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 1998, 98, 1743–1754. [CrossRef] [PubMed]
Biomolecules 2021, 11, 401 18 of 21
9. French, D. Preparation of Schardinger Dextrins. In Methods Enzymology; Elsevier: Amsterdam, The Netherlands, 1957; Volume 3,
pp. 17–20.
10. Pulley, A.O.; French, D. Studies on the Schardinger dextrins. XI: The isolation of new Schardinger dextrins. Biochem. Biophys. Res.
Commun. 1961, 5, 11–15. [CrossRef]
11. Braga, S.S. Cyclodextrins: Emerging medicines of the new millennium. Biomolecules 2019, 9, 801. [CrossRef]
12. Van Der Veen, B.A.; Van Alebeek, G.-J.W.M.; Uitdehaag, J.C.M.; Dijkstra, B.W.; Dijkhuizen, L. The three transglycosylation
reactions catalyzed by cyclodextrin glycosyltransferase from Bacillus circulans (strain 251) proceed via different kinetic mechanisms.
Eur. J. Biochem. 2000, 267, 658–665. [CrossRef]
13. Biwer, A.; Antranikian, G.; Heinzle, E. Enzymatic production of cyclodextrins. Appl. Microbiol. Biotechnol. 2002, 59, 609–617.
[CrossRef]
14. Uitdehaag, J.C.; Mosi, R.; Kalk, K.H.; van der Veen, B.A.; Dijkhuizen, L.; Withers, S.G.; Dijkstra, B.W. X-ray structures along the
reaction pathway of cyclodextrin glycosyltransferase elucidate catalysis in the alpha-amylase family. Nat. Genet. 1999, 6, 432–436.
[CrossRef]
15. Goo, B.G.; Hwang, Y.J.; Park, J.K. Bacillus thuringiensis: A specific gamma-cyclodextrin producer strain. Carbohydr. Res. 2014,
386, 12–17. [CrossRef] [PubMed]
16. Szejtli, J. Cyclodextrins. Clin. Drug Investig. 1990, 2, 11–21. [CrossRef]
17. Heredia, A.; Requena, G.; Garciasanchez, F. An approach for the estimation of the polarity of the β-cyclodextrin internal cavity. J.
Chem. Soc. Chem. Commun. 1985, 1814–1815. [CrossRef]
18. Kajtár, M.; Vikmon, M.; Morlin, E.; Szejtli, J. Aggregation of amphotericin B in the presence of γ-cyclodextin. Biopolym. Orig. Res.
Biomol. 1989, 28, 1585–1596. [CrossRef] [PubMed]
19. Street, K.W.; Acree, W.E. Estimation of the effective dielectric constant of cyclodextrin cavities based on the fluorescence properties
of pyrene-3-carboxaldehyde. Appl. Spectrosc. 1988, 42, 1315–1318. [CrossRef]
20. Caira, M.R. Cyclodextrin inclusion of medicinal compounds for enhancement of their physicochemical and biopharmaceutical
properties. Curr. Top. Med. Chem. 2019, 19, 2357–2370. [CrossRef]
21. Suvarna, V.; Gujar, P.; Murahari, M. Complexation of phytochemicals with cyclodextrin derivatives—An insight. Biomed. Pharm.
2017, 88, 1122–1144. [CrossRef]
22. Miyoshi, N.; Wakao, Y.; Tomono, S.; Tatemichi, M.; Yano, T.; Ohshima, H. The enhancement of the oral bioavailability of
γ-tocotrienol in mice by γ-cyclodextrin inclusion. J. Nutr. Biochem. 2011, 22, 1121–1126. [CrossRef]
23. Ishida, Y.; Gao, R.; Shah, N.; Bhargava, P.; Furune, T.; Kaul, S.C.; Terao, K.; Wadhwa, R. Anticancer activity in honeybee propolis:
Functional insights to the role of caffeic acid phenethyl ester and its complex with γ-cyclodextrin. Integr. Cancer 2018, 17, 867–873.
[CrossRef]
24. Oprean, C.; Mioc, M.; Csányi, E.; Ambrus, R.; Bojin, F.; Tatu, C.; Cristea, M.; Ivan, A.; Danciu, C.; Dehelean, C.; et al. Improvement
of ursolic and oleanolic acids’ antitumor activity by complexation with hydrophilic cyclodextrins. Biomed. Pharm. 2016, 83,
1095–1104. [CrossRef]
25. Stella, V.J.; Rajewski, R.A. Cyclodextrins: Their future in drug formulation and delivery. Pharm. Res. 1997, 14, 556–567. [CrossRef]
[PubMed]
26. Yuan, H.; Peng, Q.; Yong-Wei, W.; Dong-Sheng, Z.; Ming-Wan, Z.; Rui, L.; Nan, J. Host-guest interaction of β-cyclodextrin with
isomeric ursolic acid and oleanolic acid: Physicochemical characterization and molecular modeling study. J. Biomed. Res. 2017, 31,
395–407. [CrossRef] [PubMed]
27. Fenyvesi, É.; Vikmon, M.; Szente, L. Cyclodextrins in food technology and human nutrition: Benefits and limitations. Crit. Rev.
Food Sci. Nutr. 2016, 56, 1981–2004. [CrossRef]
28. Lovegrove, A.; Edwards, C.H.; De Noni, I.; Patel, H.; El, S.N.; Grassby, T.; Zielke, C.; Ulmius, M.; Nilsson, L.; Butterworth, P.J.;
et al. Role of polysaccharides in food, digestion, and health. Crit. Rev. Food Sci. Nutr. 2017, 57, 237–253. [CrossRef]
29. Kubota, Y.; Fukuda, M.; Muroguchi, M.; Koizumi, K. Absorption, distribution and excretion of BETA—Cyclodextrin and glucosyl-
BETA.-cyclodextrin in rats. Biol. Pharm. Bull. 1996, 19, 1068–1072. [CrossRef] [PubMed]
30. Van Ommen, B.; De Bie, A.; Bär, A. Disposition of 14C-α-cyclodextrin in germ-free and conventional rats. Regul. Toxicol. Pharm.
2004, 39, 57–66. [CrossRef]
31. De Bie, A.; Van Ommen, B.; Bar, A. Disposition of [14C]γ-Cyclodextrin in germ-free and conventional rats. Regul. Toxicol. Pharm.
1998, 27, 150–158. [CrossRef] [PubMed]
32. Frijlink, H.W.; Visser, J.; Hefting, N.R.; Oosting, R.; Meijer, D.K.F.; Lerk, C.F. The pharmacokinetics of β-cyclodextrin and
hydroxypropyl-β-cyclodextrin in the rat. Pharm. Res. 1990, 7, 1248–1252. [CrossRef] [PubMed]
33. Munro, I.; Newberne, P.; Young, V.; Bär, A. Safety assessment of γ-cyclodextrin. Regul. Toxicol. Pharm. 2004, 39, 3–13. [CrossRef]
[PubMed]
34. Harangi, J.; Béke, G.; Harangi, M.; Mótyán, J.A. The digestable parent cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 2011, 73,
335–339. [CrossRef]
35. Lumholdt, L.R.; Holm, R.; Jørgensen, E.B.; Larsen, K.L. In Vitro investigations of α-amylase mediated hydrolysis of cyclodextrins
in the presence of ibuprofen, flurbiprofen, or benzo[a]pyrene. Carbohydr. Res. 2012, 362, 56–61. [CrossRef]
36. Frank, D.W.; Gray, J.E.; Weaver, R.N. Cyclodextrin nephrosis in the rat. Am. J. Pathol. 1976, 83, 367–382. [PubMed]
Biomolecules 2021, 11, 401 19 of 21
37. Frijlink, H.W.; Eissens, A.C.; Hefting, N.R.; Poelstra, K.; Lerk, C.F.; Meijer, D.K.F. The effect of parenterally administered
cyclodextrins on cholesterol levels in the rat. Pharm. Res. 1991, 8, 9–16. [CrossRef]
38. Lina, B.; Bär, A. Subchronic oral toxicity studies with α-cyclodextrin in rats. Regul. Toxicol. Pharm. 2004, 39, 14–26. [CrossRef]
39. Lina, B.; Bär, A. Subchronic (13-week) oral toxicity study of α-cyclodextrin in dogs. Regul. Toxicol. Pharm. 2004, 39, 27–33.
[CrossRef]
40. Amar, M.J.A.; Kaler, M.; Courville, A.B.; Shamburek, R.; Sampson, M.; Remaley, A.T. Randomized double blind clinical trial on
the effect of oral α-cyclodextrin on serum lipids. Lipids Health Dis. 2016, 15, 1–8. [CrossRef]
41. Bellringer, M.; Smith, T.; Read, R.; Gopinath, C.; Olivier, P. β-Cyclodextrin: 52-week toxicity studies in the rat and dog. Food Chem.
Toxicol. 1995, 33, 367–376. [CrossRef]
42. Til, H.; Bar, A. Subchronic (13-Week) oral toxicity study of γ-cyclodextrin in dogs. Regul. Toxicol. Pharm. 1998, 27, 159–165.
[CrossRef]
43. Waalkens-Berendsen, D.; Verhagen, F.; Bär, A. Embryotoxicity and teratogenicity study with γ-cyclodextrin in rats. Regul. Toxicol.
Pharm. 1998, 27, 166–171. [CrossRef]
44. Asp, M.L.; Hertzler, S.R.; Chow, J.; Wolf, B.W. Gamma-cyclodextrin lowers postprandial glycemia and insulinemia without
carbohydrate malabsorption in healthy adults. J. Am. Coll. Nutr. 2006, 25, 49–55. [CrossRef]
45. GRAS Notice 678, Alpha-cyclodextrin. Available online: https://www.fda.gov/media/101653/download (accessed on 6
November 2020).
46. Wacker Biochem Corp. GRAS Notice 000046: GAMMA-CYCLODEXTRIN. Available online: http://wayback.archive-it.org/7993
/20171031055850/https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/UCM2
61675.pdf (accessed on 20 July 2020).
47. Loftsson, T.; Brewster, M.E. Pharmaceutical applications of cyclodextrins: Basic science and product development. J. Pharm.
Pharm. 2010, 62, 1607–1621. [CrossRef]
48. Mortensen, A.; Aguilar, F.; Crebelli, R.; Di Domenico, A.; Dusemund, B.; Frutos, M.J.; Galtier, P.; Gott, D.; Gundert-Remy, U.
Re-evaluation of β-cyclodextrin (E 459) as a food additive. EFSA J. 2016, 14, 257. [CrossRef]
49. European Medicines Agency. Background Review for Cyclodextrins Used as Excipients; European Medicines Agency: London, UK,
2014.
50. Hedges, A.R. Industrial applications of cyclodextrins. Chem. Rev. 1998, 98, 2035–2044. [CrossRef] [PubMed]
51. Sun, Y.-F.; Song, C.-K.; Viernstein, H.; Unger, F.; Liang, Z.-S. Apoptosis of human breast cancer cells induced by microencapsulated
betulinic acid from sour jujube fruits through the mitochondria transduction pathway. Food Chem. 2013, 138, 1998–2007. [CrossRef]
[PubMed]
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